May 2013

Dear Colleagues: 

IASLC Election for officers and members of the Board of Directors is approaching. Please see instructions below. The election process will start June 11 and run through July 16, 2013.

The World Conference on Lung Cancer in Sydney is coming closer - October 27-30, 2013. Please note that the deadline for abstract is June 21, 2013 and we hope as many members as possible will submit abstracts. Please refer to for more information. The IASLC would like to draw your attention to the special travel awards offered to the patient’s advocates (see below).

A new and improved IASLC member registration has been launched (see below) and should make the membership registration easier.

Our Asian office has now opened in Hong Kong and we are proud of presenting our Asian office staff member Vengie Lau In this Newsletter.

Many activities are currently on going, among them preparation for the IASLC Textbook in Oncology, edited by Drs. Harvey Pass, Giorgio Scagliotti and David Ball. We hope the textbook will be ready for publication in 2014.

The IASLC 40 year Anniversary in 2014 will be marked in many ways. A history book including the historical development in lung cancer biology and treatment is in preparation and will be published both as separate articles in Journal of Thoracic Oncology as well as a special book edition to be published in 2013/2014.

Our many committees are working diligently and many significant projects have been taken on board; the pathology committee is currently working on an “IASLC ALK-Diagnostic Atlas”, which will be distributed at the World conference in Sydney.

Furthermore, an extended multidisciplinary pathology committee has started preparing a new WHO/IASLC Multidisciplinary Histopathological Classification, which is planned to be completed in 2015.

The CAP/IASLC/AMP Guidelines for EGFR- and ALK testing were recently published and have received broad attention worldwide (see below). Several activities, both from IASLC and industry, have been initiated in order to implement those guidelines into clinical practice.

Many IASLC meetings are planned for 2014, please, see the meeting calendar below. We hope many IASLC members and non-members will contribute to make these meetings successful.

For those for whom it is geographical relevant, the IASLC Board of Directors and the staff want to wish all the IASLC members a happy and healthy summer season!

With best regards, 

Fred R. Hirsch, MD, PhD
Editor, IASLC Newsletter

15th World Conference on Lung Cancer – October 27 – 30, 2013


More information please go to

Applications Open for WCLC 2013 Advocacy Travel Awards

The International Association for the Study of Lung Cancer (IASLC) invites patient advocates to apply for the organization’s Advocacy Travel Awards. The IASLC will offer travel awards to a limited number of patient advocates to participate in the World Conference on Lung Cancer Oct. 27-30, 2013 in Sydney, Australia. Awardees receive free conference registration, up to four nights’ accommodations, a free IASLC Membership and a cash award for 1,000 AUD. The IASLC will award up to five travel awards. All applicants must be current members, but Advocates can join the IASLC for just US$50. Fewer than five may be awarded. Full details regarding the application process and eligibility selection are available on the WCLC Website: The submission deadline is June 21, 2013.

Update Regarding 2013 Member Renewal

IASLC has launched a new online member registration system for 2013 and all members will have received an email with renewal instructions by January 31st. If you do not receive the email, you may pay dues directly at, or please email with any questions. The new system is designed to be easier for you to renew your membership with IASLC, while also providing important updated and complete information for IASLC. It is increasingly important that are able to contact you in the event your professional location changes or if your institution’s email security prevents our communications from reaching you, so we have updated certain required fields during registration. To renew now, please visit the following link:

Members will be able to renew instantly online via credit card, or you can create a custom invoice after confirming your contact details. Also, in order to improve the services we can provide you, we are currently renovating the existing member website and it will be temporarily unavailable. The 2012 Online Member Directory is still available to members at a private website address. If you need to have the Online Member Directory link emailed to you again, please email Once the new site, features, and 2013 Member Directory are available, we will notify members directly. NOTE to American Express users: Due to certain individual security settings that may be activated on your card, you may need to confirm directly with Amex that the transaction with IASLC is intended. Thank you for your membership in IASLC.

CAP/IASLC/AMP Guidelines

The Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors has been a joint effort between the College of American Pathologists (CAP), the IALSC and the Association for Molecular Pathology (AMP). The Guidelines are released on the IASLC and JTO websites early April. A webcast with the lead authors and co-chairs of the Guideline will be given in late April. Please watch for emails or monitor the IASLC website.

IASLC Election for Officers/Board of Directors 2013

IASLC has partnered with Survey & Ballot Systems (SBS) to administer the 2013 election. To assure your election specific broadcast email arrives safely in your inbox on or around June 11, 2013, simply add the following email address as an approved sender. If you have any questions contact: Pia Hirsch at

Next ELCC meeting, March 26-29, 2014


IASLC 40th Anniversary Professor Heine H. Hansen Fellowship

As we embark on the next 40 years of the International Association for the Study of Lung Cancer, we pause to celebrate the past 40 years. The IASLC Board of Directors commemorates this notable time in the IASLC history by a 40th Anniversary Campaign to raise money for an additional fellowship in order to strengthen our education of the next generation lung cancer investigators. This fellowship will be named in Professor Heine H. Hansen’s honor. Professor Hansen was instrumental in the development of the IASLC. He was Congress President of the 2nd World Conference on Lung Cancer in Copenhagen in 1980. He served on the Board of Directors from 1985 to 1994 and served as the President from 1988-1991. Prof. Hansen was the first Executive Director of the IASLC (1991-2001) and was also the founder of the first IASLC journal Lung Cancer in 1985. He was a leader in developing international guidelines for the staging and treatment of small cell lung cancer and arranged many international workshops in this field. He received the IASLC Merit Award in 1997 and became the first Honorary Member in 2003. The IASLC fellowships benefit young researchers with the intention of encouraging innovative research in lung cancer prevention and translational medicine worldwide. Board members have made significant contributions to kick off this campaign. Please show your commitment to the IASLC 40th Anniversary Campaign by contributing to the Professor Heine H. Hansen Fellowship. 

Heine H. Hansen, M.D., Ph.D. (1938-2011)

Name: ________________________________________________________

Commitment Amount: USD 1,000 500 100 50 Other __________

Send payments to: IASLC

13100 E. Colfax Ave Unit 10

Aurora, CO 80011 


Dr. Charles Rudin, MD, PhD will be leaving Johns Hopkins University, where he is currently Cancer Center Associate Director for Clinical Research and co-Director of the Upper Aerodigestive Cancer Program, to become Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. Dr. Rudin is well known for significant contributions to translational research and will with this expertise add to the active MSKCC thoracic team.





Dr. Martin J. Edelman, MD will be leaving the University of Maryland Greenebaum Cancer Center, where he was Director of Solid Tumor Oncology to become Associate Director for Clinical Research for the University of New Mexico Cancer Center. He will be a Professor of Medicine and hold the Victor and Ruby Hansen Surface Endowed Chair in Clinical Cancer Research. He will also serve as Medical Director of the UNM Cancer Center’s Clinical Research Office and Medical Director of The New Mexico Cancer Care Alliance. In these positions he will have authority over all clinical cancer research within the institution as well as much of the State of New Mexico.




Dean, Prof. Pan-Chyr Yang, MD, PhD, Dean and Professor at the National Taiwan University in Taipei had been elected as President for the National Taiwan University by August 2013.Professor Yang is a pulmonologist with an very significant scientific contribution to the ling cancer field and also an active member of IASLC. As a leader for a very active lung cancer research group in Taiwan, he and his colleagues, have made significant contributions to the molecular characterization of lung cancer carcinogenesis and malignant tumors as well as pioneering clinical trials, particularly in the field of EGFR inhibition in collaboration with his colleague, James Yang, MD, PhD. The National Taiwan University is ranked top 51-60 on the Times World Higher Education Ranking List 2013.

Vengie Lau, MSC, New IASLC Staff Member, Asian Office. Vengie has a combined Bachelor’s degree in Pharmacology and Economics from the University of Toronto, and a Master (Msc) degree in Biochemistry from The Chinese University of Hong Kong. She has been working in the Department of Clinical Oncology, The Chinese University of Hong Kong, in Hong Kong for six years. She is currently based in Hong Kong and is responsible for developing the expansion of IASLC in the Asia region, with particular regard to the Best of WCLC meetings, membership and sponsorship. She is fluent in English, Cantonese and Mandarin and can be reached via email at



 IASLC Web-based Education Programs 


JTO is now available as an iPad app, and can be downloaded from the App Store.

Starting with September, each issue will be available within the app the same day it is mailed and posted at The first few issues will be free, but soon access will berestricted to members and paid subscribers. The same log in used for will be used to sign into the app when that feature is enabled. If you haven’t registered for a user name and password, you can do that any time at

The app includes every page of the journal in a format optimized for reading on an iPad. Users can pinch and zoom to increase the size of figures and tables, scroll through the issue with the “quick view” feature, link directly from the table of contents to articles, and email articles to colleagues. Since the issue is downloaded in its entirety, the journal can be read later even if the iPad is in “airplane” mode or no connectivity is available. Issues can be saved on the iPad, or archived after reading and downloaded again at any time, as long as the user is still an IASLC member or paid subscriber. Notifications can be enabled to provide updates when a new issue is available.

We hope you will download and use JTO on your iPad. All of the features that make JTO so valuable to your practice are included, but now you can take issues with you whenever you have your iPad.



Upcoming IASLC Workshops/Meetings 2012- 2015

15th World Conference on Lung Cancer
October 27-30, 2013
Location: Sydney, Australia
More information:

AACR- IASLC meeting on “Biology of Lung Cancer”
January 2014
San Diego, CA
More information:

14th Targeted Therapy Lung Cancer Meeting
Santa Monica, CA
February, 2014
More information:

ELCC – European Lung Cancer Conference
Geneva, Switzerland
April 2014

LalCa- Latin American Lung Cancer Conference
Lima, Peru
August, 2014

Chicago Multidisciplinary Thoracic Oncology
October 31 – November 2, 2014
More information:

APLCC- Asian Pacific lung Cancer Conference
November/December 2014

16th World Conference on Lung Cancer
September 6-10, 2015
Location: Denver, Colorado, USA
More information: pia.hirsch@ucdenver.edu11

Non – IASLC Events:


Register Now!

Lung Cancer Clinical Trials: 
Challenges & Opportunities in the Genomic Era

Friday, May 31, 2013 • 10:55 AM - 12:30 PM 
The Hyatt Regency McCormick Place 
Chicago, IL

Space is limited - Register early

This luncheon meeting presents a unique opportunity for medical professionals and 
advocates to collaborate on shaping the future of lung cancer clinical trials by boosting 
patient participation.

Attendees will engage in an interactive conversation on how we can work together to 
swiftly overcome barriers to trial accrual.

Expert-led discussions will cover topics including:

  • Challenges and solutions to boosting clinical trial accrual
  • Innovative clinical trial designs and protocols
  • Opportunities to bring trials to nonacademic medical centers and practices
  • Developing and prioritizing an agenda for action

Register online

View the meeting agenda

The University of Wisconsin School of Medicine and Public Health designates this live activity for a maximum of 1.5 AMA PRA 
Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.12
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council of 
Continuing Medical Education through the joint sponsorship of the University of Wisconsin School of Medicine and Public Health 
and the National Lung Cancer Partnership. The University of Wisconsin School of Medicine and Public Health is accredited by the 
ACCME to provide continuing medical education for physicians.

Not an official event of the 2013 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or The Conquer Cancer Foundation.